to regularly update public dashboards and keep key decision makers informed of grantee progress. All grant recipients, including states, tribes, and territories, will submit brief quarterly reports with critical information on the status of LIHEAP. The Quarterly Report forms will include questions on:

- Total households assisted,
- Performance management including the number of occurrences in which LIHEAP funding prevented the loss of or restored home energy services, and
- The estimated percentage of LIHEAP funds that have been obligated by funding component.

Grant recipients will also have an opportunity to highlight additional training/technical assistance needs/suggestions, which the Office of Community Services uses to inform support such as training and resources.

ACF also proposes several small changes to the LIHEAP Quarterly Report beginning with the Quarter 4 report due October 31, 2025 and beyond. Those changes only affect Section III of the Quarter 3 (due July 31, 2026 and beyond) and Quarter 4 reports (due October 31, 2025 and beyond). The changes to Section III involve inclusion of the primary data elements from the separate LIHEAP Carryover and Reallotment Report (OMB #: 0970–0106), which ACF wishes to discontinue use of in favor of only obtaining such data through the LIHEAP Quarterly Report. Section III would more clearly distinguish ''carryover'' fund estimated (Quarter 3) and final amounts (Quarter 4) from ''reallotment'' fund estimated and final amounts. The Quarter 3 and 4 Section III also includes a ''remarks'' field for grant recipients to complete only if they are indicating a request to carryover funds to obligate in the next FFY. The federal LIHEAP statute requires all grant recipients requesting carryover to explain why they wish to carryover and how they intend to use such carryover funds in the next year (42 U.S.C. 8626(b)(2)(A)).

Respondents: States and tribes.

Annual Burden Estimates

The estimated time per response for this report was increased from 12 to 16 hours to account for the proposed changes. These changes are expected to reduce effort overall, however, by eliminating the Carryover and Reallotment Report, as discussed above.

Instrument	Total number of respondents	Annual number of responses per respondent	Average burden hours per response	Annual burden hours
LIHEAP Quarterly Report	207	4	16	13,248

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Authority: (42 U.S.C. 8626 and 8629) and federal regulations (45 CFR 96.92).

Mary C. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2025–23909 Filed 12–23–25; 8:45 am]

BILLING CODE 4184–80–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[Office of Management and Budget #: 0970–0490]

Proposed Information Collection Activity; Generic Program-Specific Performance Progress Report

AGENCY: Administration for Children and Families, U.S. Department of Health and Human Services.

ACTION: Request for public comments.

SUMMARY: This notice describes the proposal to extend data collection under the Administration for Children and Families (ACF) Generic Program-Specific Performance Progress Report (PPR) (0970–0490). This overarching generic currently allows ACF program offices to collect performance and progress data from recipients and sub-recipients who receive funding from ACF under a grant or cooperative agreement. This generic mechanism provides the opportunity for ACF program offices to tailor requests for performance and progress data to specific funding recipients. There are no proposed changes to the overarching generic.

DATES: *Comments due* February 27, 2026.

ADDRESSES: In compliance with the requirements of the Paperwork Reduction Act of 1995, ACF is soliciting public comment on the specific aspects of the information collection described above. You can obtain copies of the proposed collection of information and submit comments by emailing *infocollection@acf.hhs.gov.* Identify all requests by the title of the information collection.

SUPPLEMENTARY INFORMATION:

Description: ACF is primarily a grant-making agency that promotes the economic and social well-being of families, children, individuals and communities with partnerships, funding, guidance, training and technical assistance. Prior to the use of this umbrella generic for program-specific PPRs, all ACF discretionary grant and cooperative agreement awards used the standard ACF PPR (#0970–0406) for post award reporting. The standard ACF PPR form requires grantees to only respond to a common set of broad questions, which could result in receipt of only qualitative or incomplete information for some programs. This one-size-fits-all approach did not adequately collect the specific data needed for particular grant programs or allow program offices to assess continuous quality improvement. Different grant programs vary in purpose, target population, and activities. Therefore, a need for program offices to customize performance measurements was identified and the generic program-specific PPR was developed.

ACF program offices have benefited from the ability to create and use a program-specific PPR that is more effective and includes specific data elements that reflects a specific program's indicators, demographics, priorities and objectives.

A generic program-specific PPR that can be tailored for program-specific needs allows program offices to collect useful data in a uniform and systematic manner. The reporting format allows program offices to gather uniform program performance data from each grantee, allowing aggregation at the program level to calculate outputs and outcomes, providing a snapshot and allowing for longitudinal analysis.

Data from a tailored program-specific PPR that demonstrates a program's successes and challenges have been useful for accountability purposes, such as required reports to Congress. Moreover, it has been useful for program management and oversight, such as identifying grantees' technical assistance needs and ensuring compliance with federal and programmatic regulations and policies. To review currently approved PPRs under this generic, see: *https://www.reginfo.gov/public/do/PRAICList?ref_nbr=202507-0970-011.*

Respondents: ACF funding recipients.

Annual Burden Estimates

The following burden estimates include burden associated with currently approved individual requests that ACF expects will be extended through this extension request and an estimate of burden for potential new requests under this generic. Burden associated with currently approved individual requests has been updated to reflect current estimates for number of respondents, time per response, and reporting cadence. Note that new requests may be submitted during this comment period, which would be included with the extension request in 2026.

POTENTIAL NEW REQUESTS

Instrument	Number of respondents	Annual number of responses per respondent	Average burden hours per response	Annual burden hours
Program Specific PPRs	900	3	6	16,200

ONGOING CURRENTLY APPROVED REQUESTS

Generic PPR title	Number of respondents	Annual number of responses per respondent	Average burden hours per response	Annual burden hours
Administration for Native Americans (ANA) American Rescue Plan Emergency Language (ARP EL) Progress Report and Post Project Report.	30	2	0.75	45.
Community Economic Development—Planning (CED–P) Grant Recipient Performance Progress Report (PPR).	31	4	2	248.
Diaper Distribution Demonstration and Research Pilot Quarterly Reporting Requirements.	252	4	3.11	3,136.
Employer Engagement Program Performance Data	24	2	5	240.
Ethnic Community Self-Help (ECSH) Program Data Indicators	27	2	2	108.
Family Violence Prevention and Services: Grants to support Culturally Specific Domestic Violence and Sexual Assault (CSDVSA) Programs.	35	2	10	700.
Family Violence Prevention and Services: Grants to support Specialized Services for Abused Parents and Children (SSAPC).	55	2	10	1,100.
Family Violence Prevention and Services: Grants to the National Domestic Violence Hotline.	2	2	10	40.
Family Violence Prevention and Services: National, Special Issue, and Culturally Specific Resource Centers.	19	2	8	304.
Head Start Collaboration Office Annual Report	54	1	4	216.
Human Trafficking Youth Prevention Education (HTYPE) Demonstration Grant Program Performance Indicators.	8	1	6	48.
Instructions for the Office of Refugee Resettlement Unaccompanied Children Program Home Study and Post-Release Service Grant Recipient Program Indicators.	25	4	0.63	63.
Microenterprise Development (MED) Program Indicators	29	2	2	116.
Office of Refugee Resettlement Refugee Family Child Care Microenterprise (RFCCMED) Program Performance Data.	15	4	2	120.
Office of Refugee Resettlement Services to Afghan Survivors of Combat (SASIC) Program Performance Data Point Tool & User Guide.	24	1	5	120.
Preschool Development Grant Birth through Five (PDG B–5) Renewal Grant Annual Performance Progress Report—2025 Revision.	28	1	8	224.
Refugee Agricultural Partnership Program (RAPP) Indicators	20	2	2.3	92.
Refugee Individual Development Accounts (IDA) Program Indicators	9	4	6	624.
IDA Program Indicators—New Cohort	13	2	3	78.
Refugee Resettlement Refugee Career Pathways (RCP) Program Performance Data.	42	2	5	420.
Regional Partnership Grant Program Semi Annual ACF Performance Progress Report.	23	2	16.5	759.
Support for Trauma-Affected Refugees (STAR) Annual Program Data Points (PDP) Tool and User Guide.	28	1	3	84.
Wilson-Fish TANF Coordination Project Performance Report Part A and B	7	2	6	84
	Total Respondents: 800.	Average # Annual Responses: 2.22.	Average Burden Hours per Response: 5.23.	Total Ongoing Annual Burden Hours: 8,969.

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Authority: 45 CFR 75.342; 45 CFR 75.301, Pub L. 111–352, section 12.

Mary C. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2025–23908 Filed 12–23–25; 8:45 am]

BILLING CODE 4184–88–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2024–E–1293]

Determination of Regulatory Review Period for Purposes of Patent Extension; ZELSUVMI

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZELSUVMI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

DATES: Anyone with knowledge that any of the dates as published (see **SUPPLEMENTARY INFORMATION**) are incorrect may submit either electronic or written comments and ask for a redetermination by February 27, 2026. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 29, 2026. See ''Petitions'' in the **SUPPLEMENTARY INFORMATION** section for more information.

ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The *https://www.regulations.gov* electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of February 27, 2026. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov.*
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include the Docket No. FDA–2024–E–1293 for ''Determination of Regulatory Review Period for Purposes of Patent Extension; ZELSUVMI.'' Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

- Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ''THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov.* Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ''confidential.'' Any information marked as ''confidential'' will not be disclosed except in accordance with § 10.20 (21 CFR 10.20) and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: *https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.*

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to *https://www.regulations.gov* and insert the docket number, found in brackets in the heading of this document, into the ''Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

FOR FURTHER INFORMATION CONTACT: Jack Dan, Office of Regulatory Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6200, Silver Spring, MD 20993, 240–402–6940.

SUPPLEMENTARY INFORMATION:

I. Background

The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98–417) and the Generic Animal Drug and Patent Term Restoration Act (Pub. L. 100–670) generally provide that a patent may be